These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 33786727)
21. Identification of novel TMPRSS2 inhibitors against SARS-CoV-2 infection: a structure-based virtual screening and molecular dynamics study. Manandhar S; Pai KSR; Krishnamurthy PT; Kiran AVVVR; Kumari GK Struct Chem; 2022; 33(5):1529-1541. PubMed ID: 35345416 [TBL] [Abstract][Full Text] [Related]
22. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease. Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858 [TBL] [Abstract][Full Text] [Related]
23. Identification, virtual screening and molecular dynamic analysis of novel TMPRSS2 inhibitors from natural compound database as potential entry-blocking agents in SARS-CoV-2 therapy. Manandhar S; Pai KSR; Krishnamurthy PT; Kiran AVVVR; Kumari GK Struct Chem; 2022; 33(5):1609-1617. PubMed ID: 35754942 [TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study. Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y Eur J Pharmacol; 2021 Apr; 896():173922. PubMed ID: 33539819 [TBL] [Abstract][Full Text] [Related]
25. Relaxed complex scheme and molecular dynamics simulation suggests small molecule inhibitor of human TMPRSS2 for combating COVID-19. Vuai SAH; Ogedjo MM; Isaac O; Sahini MG; Swai HS; Shadrack DM J Biomol Struct Dyn; 2022; 40(24):13925-13935. PubMed ID: 34751094 [TBL] [Abstract][Full Text] [Related]
26. Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies. Rajagopal K; Varakumar P; Aparna B; Byran G; Jupudi S J Biomol Struct Dyn; 2021 Sep; 39(15):5551-5562. PubMed ID: 32720578 [TBL] [Abstract][Full Text] [Related]
27. Exploring the phytochemicals of Gurung AB; Ali MA; Lee J; Aljowaie RM; Almutairi SM J King Saud Univ Sci; 2022 Aug; 34(6):102155. PubMed ID: 35702062 [No Abstract] [Full Text] [Related]
29. Computational screening of phytochemicals from three medicinal plants as inhibitors of transmembrane protease serine 2 implicated in SARS-CoV-2 infection. Oyedara OO; Agbedahunsi JM; Adeyemi FM; Juárez-Saldivar A; Fadare OA; Adetunji CO; Rivera G Phytomed Plus; 2021 Nov; 1(4):100135. PubMed ID: 35403085 [TBL] [Abstract][Full Text] [Related]
30. Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells. Icho S; Rujas E; Muthuraman K; Tam J; Liang H; Landreth S; Liao M; Falzarano D; Julien JP; Melnyk RA Antimicrob Agents Chemother; 2022 Jul; 66(7):e0043922. PubMed ID: 35703551 [TBL] [Abstract][Full Text] [Related]
31. Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies. Kishk SM; Kishk RM; Yassen ASA; Nafie MS; Nemr NA; ElMasry G; Al-Rejaie S; Simons C Molecules; 2020 Oct; 25(21):. PubMed ID: 33137894 [TBL] [Abstract][Full Text] [Related]
32. In silico study of alkaloids with quercetin nucleus for inhibition of SARS-CoV-2 protease and receptor cell protease. Mohebbi A; Eskandarzadeh M; Zangi H; Fatehi M PLoS One; 2024; 19(4):e0298201. PubMed ID: 38626042 [TBL] [Abstract][Full Text] [Related]
33. Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture. Wettstein L; Knaff PM; Kersten C; Müller P; Weil T; Conzelmann C; Müller JA; Brückner M; Hoffmann M; Pöhlmann S; Schirmeister T; Landfester K; Münch J; Mailänder V Commun Biol; 2022 Jul; 5(1):681. PubMed ID: 35804152 [TBL] [Abstract][Full Text] [Related]
34. The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular docking analysis. Marciniec K; Beberok A; Boryczka S; Wrześniok D Pharmacol Rep; 2021 Dec; 73(6):1765-1780. PubMed ID: 34052981 [TBL] [Abstract][Full Text] [Related]
35. Targeting mechanism for SARS-CoV-2 Zhao X; Luo S; Huang K; Xiong D; Zhang JZH; Duan L Nanoscale; 2021 Nov; 13(45):19218-19237. PubMed ID: 34787160 [TBL] [Abstract][Full Text] [Related]
36. Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies. M P; Reddy GJ; Hema K; Dodoala S; Koganti B Eur J Pharmacol; 2021 Jan; 890():173688. PubMed ID: 33130280 [TBL] [Abstract][Full Text] [Related]
37. Identification of potent inhibitors against transmembrane serine protease 2 for developing therapeutics against SARS-CoV-2. Mamun AA; Akter F; Khan M; Ahmed SS; Uddin MG; Tasfia NT; Efaz FM; Ali MA; Sultana MUC; Halim MA J Biomol Struct Dyn; 2022; 40(23):13049-13061. PubMed ID: 34590967 [TBL] [Abstract][Full Text] [Related]